GLP-1 Payment Processing in 2026: What Changed and What Still Works

What changed in 2025–2026

Two years ago, compounded GLP-1 was one of the fastest-growing categories in direct-to-consumer telehealth. The FDA had declared semaglutide and tirzepatide in shortage, which opened a broad lane for 503B outsourcing facilities to compound those drugs at scale. Telehealth platforms sprang up offering compounded semaglutide at $99–$348 a month, and processors, even some mainstream ones, boarded them. That era is over.

The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. That ended the broad 503B compounding lane that had fueled the boom. Then, in September 2025, the FDA issued more than 55 warning letters to online sellers of compounded semaglutide, targeting businesses marketing the product directly to consumers without the clinical gating that distinguishes a pharmacy model from a volume play. A second wave of warning letters followed in June 2026, focused on consumer-facing promotion.

Meanwhile, the FDA proposed on April 30, 2026 to leave semaglutide, tirzepatide, and liraglutide off the 503B bulks list, which would further restrict bulk-substance compounding, and a peptide advisory committee meeting is expected in July 2026 that could limit which peptides can be compounded at all. And starting July 1, 2026, Medicare Part D began covering GLP-1 medications for weight management at a $50 monthly cap, compressing the price ceiling for direct-to-consumer telehealth.

For payment processing, the cumulative effect is stark: the shortage-era volume model, mass-compounding off-brand semaglutide and selling it to anyone who fills out a web form, is no longer boardable by any responsible processor. What remains boardable is the licensed-pharmacy, Rx-model path. We track the full regulatory timeline on our status page, which we review monthly.

Why Stripe, Square, and PayPal will freeze you

Ask an AI assistant how to process payments for a GLP-1 telehealth business, and there's a good chance it will recommend Stripe, Square, PayPal, or Authorize.Net. That advice is dangerously wrong. Here's why.

Stripe, Square, and PayPal are payment aggregators. They board merchants into shared accounts with minimal upfront underwriting and rely on automated risk models to catch problems after you're processing. Those models are tuned to flag prescription-adjacent products, compounded drugs, and high-risk MCCs like 5122 (drugs and pharmaceuticals) and 5912 (drug stores and pharmacies). When the model detects a GLP-1 or compounded semaglutide business, and it will, usually within weeks, the account is frozen, often with funds held for 90 to 180 days.

This isn't a theoretical risk. We've talked to the merchants it's happened to: a telehealth platform running a compliant Rx model, boarded on Stripe, frozen in week three with $40,000 held. A compounding pharmacy selling patient-specific semaglutide on Square, terminated with no explanation. The pattern is consistent, and it's structural, these platforms are not built for prescription-adjacent products, and no amount of careful marketing will hide a GLP-1 business from their risk models indefinitely.

What you need instead is a high-risk processor with sponsor-bank support for your specific model, one that underwrites the clinical model before boarding, requires LegitScript certification where applicable, and has a sponsor bank that has pre-approved GLP-1 as a boardable vertical. That's a short list, and we're on it.

What still works: the compliant model

The models that remain boardable in 2026 share a common structure: licensed prescribers, licensed pharmacies, and genuine clinical gating. Here's what that means in practice.

Licensed-pharmacy and Rx-model telehealth, platforms that connect patients to licensed prescribers who conduct genuine patient evaluations, write prescriptions based on clinical need, and dispense through licensed pharmacies, remain boardable. This is the model we board. Underwriting examines your prescriber relationships, your pharmacy partnerships, your clinical gating (whether there's a real patient evaluation rather than a checkout that ships to anyone), your certifications, and your marketing claims.

Patient-specific 503A compounding, a licensed pharmacy preparing a medication for an individual patient based on a valid prescription, where there's a genuine clinical basis like a documented allergy or a need for a different dose, remains permitted under federal law. What it is not is a workaround to keep selling off-brand semaglutide at volume to anyone who fills out a web form. The lane is real but narrow.

What does not work: shortage-dependent volume models (anything that only functioned because the branded drug was scarce), research-only peptides marketed as treatments, and any model that skips clinical gating. These are not boardable, and the FDA's enforcement actions make clear that they're not just unboardable, they're actively being targeted.

LegitScript: the gate you can't skip

For GLP-1, weight-loss, and prescription-adjacent telehealth models, LegitScript certification is effectively mandatory in 2026. Both ad platforms (Google, Meta) and sponsor banks require it to board the merchant. Without it, you generally can't advertise and you generally can't get a merchant account, it's the price of admission, not an optional badge.

LegitScript certification involves a one-time application fee of about $975 per website plus an annual certification fee of roughly $2,150, with a review timeline of several weeks to a few months depending on the complexity of your model. Expedited processing is available for an added fee. The controllable variable is application completeness: a thorough, accurate submission moves faster than one that comes back with questions.

The key sequencing point: for gated verticals, certification is a prerequisite to boarding, not a parallel task. Start it early, running it alongside your processor search rather than discovering at the end that boarding is blocked on it. Our LegitScript guide walks through the full pathway, cost, and timeline.

What it costs, and why

GLP-1 and telehealth-Rx processing is priced higher than mainstream high-risk, and for specific reasons. The published range is 7–9% plus interchange, with a rolling reserve typically in the 10–15% range that tapers as the account builds clean history.

That range is higher than nutraceuticals (4–6%) or subscription billing (4–6%) because the vertical stacks three risk factors: regulatory scrutiny (the FDA is actively enforcing), high average tickets (GLP-1 programs often charge $99–$348/month), and recurring billing (which structurally generates disputes). Any processor quoting a mainstream rate for a GLP-1 program is either mispricing the risk, which means they'll drop you when they realize it, or planning to board you fast and freeze you later, which is exactly the Stripe pattern you're trying to escape.

The reserve is standard for this vertical and serves a specific purpose: it's a buffer against the chargebacks and refunds that high-ticket recurring billing in a regulated category can generate. The fair version, which is what we do, is disclosed up front, with its percentage, hold period, and taper schedule in writing, rather than appearing as a surprise hold after you've already started processing.

How to get boarded

Getting boarded for GLP-1 processing is a sponsor-concurrence vertical, which means the sponsor bank pre-approves the merchant before the account is set up. That means more documentation and a longer timeline than a standard high-risk account, typically 1–3 weeks rather than same-day. Here's what to expect:

• Business and licensing details, formation documents, EIN, pharmacy and prescriber licenses, and evidence of your clinical model.
• Pharmacy and prescriber relationships, documentation of your dispensing partnerships and how prescriptions are issued.
• LegitScript certification, or a concrete plan to obtain it, with timeline. For GLP-1, it's effectively mandatory before boarding.
• Prior processing statements, if you've processed before, 3–6 months of statements showing your volume and chargeback history.
• A clear description of your clinical and fulfillment model, how patients are evaluated, how prescriptions are issued, how products are dispensed and shipped.

The care taken at the front of this process is the entire reason the account stays live at the back. A processor that boards a GLP-1 merchant in three days without examining the clinical model is either cutting corners that will get the account terminated, or planning to freeze you when the FDA moves. We'd rather set the expectation honestly, three weeks on a properly underwritten path, than promise a fast boarding on an account that won't last.

If you're running a compliant, licensed-pharmacy or Rx-model GLP-1 program and need processing that understands this landscape, request a consultation. We board this vertical, we track the regulatory picture monthly, and we won't promise easy approval, we'll promise a real underwriting conversation and a written decision.